Ovarian Cancer Review

Researchers compared primary high grade serous ovarian carcinoma tumors and their matched metastasis, showing evidence of separating the 2 sample types and potentially predicting patient survival.

Research suggests that oncogene S100A10 may play a definitive role in the progression of ovarian cancer and its expression levels may affect sensitivity to carboplatin.

The approval comes one day after the FDA approved niraparib for the same subset of ovarian cancer.